CRMDCRMDHealthcare · Biotechnology

CRMD Stock Forecast: CorMedix, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$4.65
−3.93% on the day

The 5 Wall Street analysts covering CorMedix, Inc. hold a median 12-month price target of $15 — +222.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 13 Nov 2026 — in the upper half.

Market cap
$384.7M
Ticker Nerd rank
56/ 100
Median analyst target
$15
Analysts covering
5
Revenue$99.3M+149.9% y/y
Operating income$42.9M
Net income$26.0M
Free cash flow$85.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.6%
1M
−37.1%
YTD
−60.0%
1Y
−58.5%
From 52W high
−63.5%
From 52W low
0.0%
$5
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CorMedix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
56/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
86
Accruals
76
Size
57
Volatility
48
Growth
41
Revisions
40
Momentum
30
Issuance
15

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CRMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26CRMDHigh $19Median $15Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $14Median $15High $19

The green dot is the last close — the median target sits +222.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
13 Nov 2026OppenheimerReiteratesOutperform$15 → $13
13 Nov 2026RBC CapitalMaintainsOutperform$15 → $14
12 Nov 2026NeedhamMaintainsBuy$14 → $12
10 Nov 2026NeedhamMaintainsBuy$12 → $14
10 Nov 2026RBC CapitalMaintainsOutperform$14 → $15
2 Nov 2026NeedhamMaintainsBuy$15 → $12
2 Nov 2026NeedhamMaintainsBuy—
19 Oct 2026NeedhamReiteratesBuy—
19 Oct 2026NeedhamReiteratesBuy$15
23 Sept 2026OppenheimerInitiatesOutperform—
23 Sept 2026OppenheimerInitiatesOutperform$15
14 Aug 2026RBC CapitalMaintainsOutperform—
14 Aug 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform$14 → $13
7 July 2026RBC CapitalMaintainsOutperform—
28 Apr 2026CitizensReiteratesMarket Outperform—
28 Apr 2026Leerink PartnersMaintainsOutperform—
28 Apr 2026RBC CapitalMaintainsOutperform—
27 Apr 2026D. Boral CapitalMaintainsBuy—
27 Apr 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CRMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CRMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, CorMedix, Inc. returned −58.5% against +13.4% for the S&P 500, dividends included.

CRMD vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26CRMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−2.1%
Analysts raising
2
Analysts cutting
3
Fundamentals

CorMedix, Inc. (CRMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.4×

Cheaper than 69% of US stocks

Price / sales
0.9×

Cheaper than 69% of US stocks

Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
0.8×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−47.7%

Higher than 6% of US stocks

Earnings growth (YoY)
149.9%

Higher than 88% of US stocks

Gross margin
75.0%

Higher than 87% of US stocks

Operating margin
41.0%

Higher than 94% of US stocks

Net margin
15.5%

Higher than 78% of US stocks

Returns & dividend
Return on equity
15.3%

Higher than 74% of US stocks

Return on assets
12.7%

Higher than 95% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CorMedix, Inc. (CRMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CorMedix, Inc. has a market value of $384.7M and an enterprise value of $177.3M.

  • Revenue in the twelve months to 30 June 2026: $459.6M. The latest quarter shrank 47.7% year on year.

  • Net income over the same four quarters: $187.2M, a 40.7% net margin.

  • Diluted earnings per share, trailing twelve months: $2.14.

  • Free cash flow in the twelve months to 30 June 2026: $250.4M.

  • Shares outstanding: 77.7M.

  • Trailing P/E: 2.4×; forward P/E: 13.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CorMedix, Inc. employs 191 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Nov 2026

Data provided by Twelve Data

Peers

CRMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRMDCorMedix, Inc.$384.7M56
CCCCC4 Therapeutics, Inc.$362.4M64
ASPEAspen Neuroscience, Inc.$366.1M0
LYELLyell Immunopharma, Inc.$350.4M75
ALECAlector, Inc.$376.6M95
RZLTRezolute, Inc.$349.8M42
YDESYD Bio Ltd.$345.7M3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CorMedix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRMD news & analysis

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

Zacks Investment Research · 13 Nov 2026negative

CorMedix beat Q3 earnings and revenue estimates, but DefenCath pricing pressure hurt sales. The excerpt also notes progress with Rezzayo and a planned Heron acquisition shaping the company’s 2027 outlook.

Why it matters — CRMD watchers may weigh the quarterly beat against sales pressure and the developments cited for its 2027 outlook.

CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript

Seeking Alpha · 12 Nov 2026neutral

The provided text identifies a CorMedix Inc. (CRMD) Q3 2026 earnings call transcript but gives no details about the call.

Why it matters — CRMD watchers may note that an earnings-call transcript is available, but the excerpt does not provide information about the company’s results or outlook.

What CorMedix (CRMD) Said on Its Q3 Earnings Call

MarketBeat · 12 Nov 2026neutral

CorMedix reported lower third-quarter revenue as DefenCath entered a new reimbursement period. Management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment.

Why it matters — The update covers changes in revenue, a planned asset acquisition, and delayed guidance for a treatment relevant to CRMD watchers.

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 12 Nov 2026positive

CorMedix reported a quarterly loss of $0.04 per share, compared with the Zacks consensus estimate of a $0.09 loss. A year earlier, it reported earnings of $0.57 per share.

Why it matters — The results show the quarterly loss was narrower than the consensus estimate, while earnings were lower than a year ago.

Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Nov 2026neutral

CorMedix reported third-quarter 2026 consolidated revenue of $54.5 million, a net loss of $14.7 million and adjusted EBITDA of $3.1 million. The company also noted its recently announced acquisition of Heron Therapeutics assets, maintained its 2026 revenue guidance and narrowed its adjusted EBITDA guidance.

Why it matters — The results and updated guidance provide CRMD watchers with current financial and business information, including the effect of the announced asset acquisition.

FAQ

Frequently asked questions about CRMD stock

What is the CRMD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering CorMedix, Inc. have a median 12-month price target of $15, with estimates ranging from $14 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRMD stock a buy right now?

Of the 5 analysts covering CorMedix, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CorMedix, Inc. 56 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRMD?

As at 13 Nov 2026, CorMedix, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will CRMD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +222.6% from the last close, and Ticker Nerd's factor model ranks CorMedix, Inc. 56 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRMD stock forecast for 2030?

No analyst covering CorMedix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $19 over the next 12 months.

How has CRMD stock performed over the past year?

CorMedix, Inc. returned -58.5% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CorMedix, Inc. do?

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

What is the latest news on CRMD?

The most recent item we track (Zacks Investment Research, 13 Nov 2026): "CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates". CorMedix beat Q3 earnings and revenue estimates, but DefenCath pricing pressure hurt sales. The excerpt also notes progress with Rezzayo and a planned Heron acquisition shaping the company’s 2027 outlook.

Company

About CorMedix, Inc.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through central venous catheters. The company serves healthcare providers and dialysis settings, where preventing bloodstream infections is a critical part of patient care. CorMedix also operates as a specialty pharmaceutical business with a product portfolio aimed at acute care markets and other medically important settings. Headquartered in Berkeley Heights, New Jersey, CorMedix Inc. plays a targeted role in the healthcare market by addressing complications associated with vascular access and chronic kidney failure treatment.

CEO Mr. Joseph Todisco MBA · 191 employees · United States · https://cormedix.com